DHR vs ORCL: Which Is the Better Buy?

Side-by-side comparison of Danaher Corporation and Oracle Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-10.
Danaher Corporation Β· Healthcare
$195.98
+7.9% upside to fair value
Grade B High Quality
VS
Oracle Corporation Β· Technology
$184.31
+14.0% upside to fair value
Grade C High Quality
QuantHub Verdict
ORCL has more upside to fair value (+14.0%). ORCL trades at a lower forward P/E (31.0x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric DHR ORCL
Current Price $195.98 $184.31
Fair Value Estimate $211.54 $210.13
Upside to Fair Value +7.9% +14.0%
Market Cap $138.7B $530.1B
Forward P/E 37.8x 31.0x
EV / EBITDA 22.8x 20.4x
Price / Sales 5.6x 7.9x
Price / FCF 26.2x -22.4x
Revenue Growth YoY +3.7% +20.6%
Gross Margin 60.7% 65.8%
Operating Margin 21.0% 30.8%
Return on Equity 7.1% 50.4%
Dividend Yield 0% 0%
FCF Yield 3.81% β€”
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
DHR β€” Danaher Corporation
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
ORCL β€” Oracle Corporation
Oracle Corporation is a leading enterprise software and cloud infrastructure provider with a durable competitive moat driven by its extensive software portfolio, strong cloud growth, and stable leadership. The company reported $57.4 billion in revenue for fiscal 2025, growing 8% year-over-year, with cloud services and license support growing 12%. Oracle's cloud infrastructure (OCI) is a key growt…
Accumulation Zones
Metric DHR ORCL
Zone Low $158.66 $157.60
Zone High $179.81 $178.61
In Buy Zone? No No
← DHR Research    ORCL Research β†’    All Research